Tags

Type your tag names separated by a space and hit enter

Validation--how much can the world afford? Are we getting value for money?
J Pharm Sci Technol. 1994 Jan-Feb; 48(1):45-8.JP

Abstract

The author raises questions not usually considered in discussions of validation: "How much validation can the world afford?," "Are we getting value for money?," and "What's in it for the patient?." The paper develops the theme that, while validation is undoubtedly important, the pharmaceutical industry has not given adequate thought as to whether the benefits of validation outweigh the costs in implementation of validation.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8004419

Citation

Anisfeld, M H.. "Validation--how Much Can the World Afford? Are We Getting Value for Money?" Journal of Pharmaceutical Science and Technology : the Official Journal of PDA, vol. 48, no. 1, 1994, pp. 45-8.
Anisfeld MH. Validation--how much can the world afford? Are we getting value for money? J Pharm Sci Technol. 1994;48(1):45-8.
Anisfeld, M. H. (1994). Validation--how much can the world afford? Are we getting value for money? Journal of Pharmaceutical Science and Technology : the Official Journal of PDA, 48(1), 45-8.
Anisfeld MH. Validation--how Much Can the World Afford? Are We Getting Value for Money. J Pharm Sci Technol. 1994 Jan-Feb;48(1):45-8. PubMed PMID: 8004419.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Validation--how much can the world afford? Are we getting value for money? A1 - Anisfeld,M H, PY - 1994/1/1/pubmed PY - 1994/1/1/medline PY - 1994/1/1/entrez SP - 45 EP - 8 JF - Journal of pharmaceutical science and technology : the official journal of PDA JO - J Pharm Sci Technol VL - 48 IS - 1 N2 - The author raises questions not usually considered in discussions of validation: "How much validation can the world afford?," "Are we getting value for money?," and "What's in it for the patient?." The paper develops the theme that, while validation is undoubtedly important, the pharmaceutical industry has not given adequate thought as to whether the benefits of validation outweigh the costs in implementation of validation. SN - 1076-397X UR - https://www.unboundmedicine.com/medline/citation/8004419/Validation__how_much_can_the_world_afford_Are_we_getting_value_for_money L2 - http://journal.pda.org/cgi/pmidlookup?view=long&pmid=8004419 DB - PRIME DP - Unbound Medicine ER -